Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Adaptive Biotechnologies reported a revenue of $46.44 million for the quarter ended September 2024, reflecting a year-over-year increase of 22.5% and a surprise of +14.41% over the Zacks Consensus Estimate of $40.59 million [1] - The company's EPS was -$0.22, an improvement from -$0.35 in the same quarter last year, with a surprise of +26.67% compared to the consensus estimate of -$0.30 [1] Revenue Breakdown - ClonoSEQ test volume reached 19,600, slightly above the average estimate of 19,534 based on three analysts [3] - Total MRD revenues were reported at $37.47 million, exceeding the average estimate of $33.56 million, representing a significant year-over-year increase of 51.9% [3] - Total Immune Medicine revenues were $8.97 million, surpassing the average estimate of $6.74 million, but showing a year-over-year decline of 32.3% [3] Stock Performance - Shares of Adaptive Biotechnologies have increased by 15% over the past month, outperforming the Zacks S&P 500 composite, which saw a change of +3.2% [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [4]